Press Releases
Whether it’s a new product enabling ground-breaking research, a strategic partnership with a customer, or a charitable partnership that supports our mission, we’ve always got something going on. Below you’ll find our most recent press releases as well as a filter to further streamline your search.
Contact
For journalist inquiries only, contact:
Rachel Bloom-Baglin
Phone: +49 (6151) 72-44461
Apr 17, 2024
MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube TourMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, officially kicked off its global 2024 Curiosity Cube tour today in Darmstadt, Germany.
Apr 16, 2024
Merck Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety TestingMerck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind.
Feb 13, 2024
Press Release Test AEM3-605Teaser text.
Nov 25, 2022
AEM2-823-PR - - Merck Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-UpMerck, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. The business combination is expected to enable the Life Science business to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years.
Nov 01, 2022
Jul 15, 2021
Press Release 0520 Merck ROW HeadlinePress Release 0520 Merck ROW Teaser
Aug 18, 2019
Merck Granted 20 CRISPR Patents Total WorldwideMerck today announced that the European, Israeli, South Korean and U.K. intellectual property offices have issued formal notices allowing seven additional Merck patent application claims covering CRISPR gene-editing technology.
Apr 01, 2019
Merck Elevates its BioContinuum™ Platform Strategy to Deliver ‘ContiGuous’ BioprocessingMerck today unveiled its BioContinuum™ Buffer Delivery Platform, a new building block in the BioContinuum™ Platform for next-generation bioprocessing, at INTERPHEX in New York City.
To continue reading please sign in or create an account.
Don't Have An Account?